Interstitial Fluid Composition in Patients With Septic Versus Non-septic Shock: an Exploratory Pilot Study

NCT ID: NCT05039151

Last Updated: 2025-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

26 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-25

Study Completion Date

2025-07-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Septic shock is a common reason for admission to intensive care units and severe infections are responsible for 6 million deaths a year worldwide. Fluid management appears to be a major issue in resuscitation and particularly in septic shock, where generalised oedema is almost systematic and is a major factor in poor prognosis during sepsis. The formation of oedema corresponds to an imbalance, according to Frank-Starling's law of the heart, between the vascular compartment and the interstitial compartment, which is composed of the interstitial liquid and an extracellular matrix. This extracellular matrix consists essentially of a network of collagen and fibroblast fibres. Even though all of the plasma in the body transits through the interstitium in 24 hours and desite its major importance in the microenvironment and intercellular communication, the interstitial compartment has not been fully described. In oncology, interstitial tissue seems to contribute to tumour growth through changes in matrix composition and pressure in the interstitium. This pressure actively contributes to the regulation of transcapillary filtration, and thus to the oedema and hypovolemia observed during sepsis. In usual conditions, the fibroblasts exert a tension on the collagen fibres of the matrix via integrin Beta-1 (ITGB1). This tension is released under the action of pro-inflammatory mediators, resulting in negative pressure which potentiates the formation of oedema.

It has been shown in an endotoxemia model that there is a thousandfold higher concentration of ITGB1 in the interstitium compared to the vascular compartment, suggesting a local secretion of this cytokine. The alteration of the extracellular matrix could also play a role in the perpetuation of oedema during septic shock. Considered as an organ in its own right, interstitial tissue is far from playing a passive role between the vascular compartment and the cells. The hypothesis is that interstitial fluid analysis could improve our understanding of the physiopathology of sepsis, in particular on the alteration of the mechanisms of fluid movement regulation, which remains very poorly understood while being closely associated with prognosis in patients with sepsis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Interstitial Liquid Septic Shock

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

septic shock

50 patients with a diagnosis of septic shock established within 24 hours of admission with oedemas

interstitial fluid sampling

Intervention Type BIOLOGICAL

The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.

blood sampling

Intervention Type BIOLOGICAL

A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2

control

35 non-septic patients with oedema from another cause

interstitial fluid sampling

Intervention Type BIOLOGICAL

The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.

blood sampling

Intervention Type BIOLOGICAL

A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

interstitial fluid sampling

The sample will be taken via three small catheters (thinner than the catheters used for conventional infusions) under the skin in the abdomen. 1 to 10 ml of interstitial liquid will be collected. A sample will be taken on D1 and D2.

Intervention Type BIOLOGICAL

blood sampling

A blood sample (3 x 5 ml EDTA tubes) will be taken simultaneously. A sample will be taken on D1 and D2

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient under mechanical ventilation and sedation
* Patient and/or trusted person (health care proxy) or close relative who has given their oral consent after being informed,
* Age ≥ 18 years old,


* Diagnosis within 24 hours of admission of septic shock as defined by :
* A probable or confirmed infection
* And a SOFA score ≥ 2
* And the need to introduce vasopressors to obtain a MAP ≥ 65 mmHg despite adequate vascular filling
* And an arterial lactate \> 2 mmol/l
* Norepinephrine dose greater than 0.1 μg/kg/min
* Septic shock present for less than 48 hours


\- Absence of sepsis and shock from any cause within 2 months prior to inclusion

Exclusion Criteria

* Disseminated intravascular coagulation (DIC) with haemorrhagic syndrome
* Acute condition that can mimic sepsis :
* Acute pancreatitis without signs of superinfection
* Metformin Intoxication
* Patient with an unfavourable prognosis within 24 hours
* Patient under legal protection (safeguard of justice, guardianship or tutelage)
* Pregnant or breastfeeding women
* Patient not affiliated to national health insurance
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chu Dijon Bourgogne

Dijon, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LABRUYERE CRBFC-A 2020

Identifier Type: -

Identifier Source: org_study_id